Get started
Author

Andrius Žučenka

Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
2025 · Martha L. Arellano, Michael J. Thirman, et al. · Blood · 75
PDF
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
2023 · Michael Lübbert, Pierre W Wijermans, et al. · The Lancet Haematology · 40
PDF
Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant
2023 · Andrius Zucenka, Ghayas C. Issa, et al. · Blood · 23
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation
2021 · Andrius Zucenka, Vilmante Vaitekenaite, et al. · Bone Marrow Transplantation · 22
Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
2024 · Ibrahim Aldoss, Ghayas C. Issa, et al. · Blood · 18
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
2023 · Rory M Shallis, Naval Daver, et al. · The Lancet Haematology · 17
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies
2020 · Andrius Zucenka, Regina Pileckyte, et al. · European Journal Of Haematology · 17
Oxidative phosphorylation inhibition induces anticancerous changes in therapy‐resistant–acute myeloid leukemia patient cells
2019 · Aida Vitkevičienė, Vytautas Janulis, et al. · Molecular Carcinogenesis · 16
Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
2021 · Andrius Zucenka, Kazimieras Maneikis, et al. · Annals of Hematology · 14
PDF
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
2019 · Aida Vitkevičienė, Giedrė Skiauterytė, et al. · Journal of Oncology · 14
PDF
The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
2022 · Justinas Daraskevicius, Vidmantas Petraitis, et al. · Journal of Fungi · 10
PDF
Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia
2022 · Aida Vitkevičienė, Giedrė Skliutė, et al. · Cancers · 8
PDF
Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan
2020 · Kazimieras Maneikis, Ugne Ringeleviciute, et al. · IJC Heart & Vasculature · 7
PDF
Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
2020 · Rūta Čepulytė, Andrius Žučenka, et al. · Case Reports in Hematology · 6
PDF
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics
2026 · Luis E. Aguirre, Jan Philipp Bewersdorf, et al. · Blood Neoplasia · 5
Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study
2025 · Ibrahim Aldoss, Ghayas Issa, et al. · Blood · 5
PDF
Mesenchymal stromal cells for steroid-refractory biopsy-proven grade III-IV acute Graft-versus-Host Disease with predominant gastrointestinal involvement
2025 · Adomas Bukauskas, Renata Jucaitienė, et al. · Frontiers in Immunology · 5
PDF
Outcomes and Risk Factors of Critically Ill Patients with Hematological Malignancy. Prospective Single-Centre Observational Study
2021 · Šarūnas Judickas, Raimundas Stasiūnaitis, et al. · Medicina · 5
PDF
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis—insights from a multicenter study
2024 · Yu-Hung Wang, Chao-Hung Wei, et al. · Leukemia · 4
Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3 ‐mutated acute myeloid leukaemia
2024 · Andrius Zucenka, Laimonas Griskevicius · British Journal of Haematology · 4
PDF
Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies
2022 · Lukas Kevlicius, Ruta Cepulyte, et al. · Bone Marrow Transplantation · 4
Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
2022 · Veronika Borutinskaitė, Andrius Žučenka, et al. · Frontiers in Genetics · 4
PDF
Etoposide + Granulocyte Colony-Stimulating Factor and Optional Plerixafor in Patients Who Failed Chemomobilization with or without Plerixafor
2019 · Andrius Zucenka, Valdas Peceliunas, et al. · Transplantation and Cellular Therapy · 4
Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)
2025 · Marc Raaijmakers, Hartmut Döhner, et al. · Blood · 3
AML-111: Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)
2025 · Ibrahim Aldoss, Ghayas C. Issa, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Works count: 103
Citation count: 367
H-index: 10
I10-index: 11
Year
Topic
Type